Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: A pilot open‐label study

Executive dysfunction (ED) is a prominent and often disabling feature of cognitive impairment in Parkinson's disease (PD). Few studies have examined treatments. Given the role of noradrenergic pathology in ED, atomoxetine, a norepinephrine reuptake inhibitor indicated for attention deficit hyperactivity disorder (ADHD), may be a potential treatment for PD‐related ED. Twelve patients with PD and disabling ED completed an 8‐week pilot open‐label, flexible dose (25–100 mg/day) trial of atomoxetine. On primary outcome measures, atomoxetine was associated with improved ED based on the Clinical Global Impression‐Change Scale (75% positive response rate; 95% CI: 43–95%, P < 05) and behavioral measures of ED [Frontal Systems Behavior Scale (FrSBE) Executive Dysfunction and Connors Adult ADHD Rating Scale (CAARS) inattention/memory subscales]. Adverse effects included sleep and gastrointestinal disturbances and hypomania. Atomoxetine is tolerable in PD and may benefit clinical manifestations of ED, warranting further study in controlled trials. © 2008 Movement Disorder Society

[1]  J. Morris,et al.  Validity and Reliability of the Alzheimer's Disease Cooperative Study‐Clinical Global Impression of Change , 2017 .

[2]  Janneke Koerts,et al.  Cognitive dysfunction in non-demented Parkinson's disease patients: Controlled and automatic behavior , 2009, Cortex.

[3]  W D Heiss,et al.  STN-DBS activates the target area in Parkinson disease , 2008, Neurology.

[4]  Didier Hannequin,et al.  Microsubthalamotomy: An immediate predictor of long‐term subthalamic stimulation efficacy in Parkinson disease , 2008, Movement disorders : official journal of the Movement Disorder Society.

[5]  T. Robbins,et al.  Similar Effects of the Selective Noradrenaline Reuptake Inhibitor Atomoxetine on Three Distinct Forms of Impulsivity in the Rat , 2008, Neuropsychopharmacology.

[6]  T. Robbins,et al.  Atomoxetine Improved Response Inhibition in Adults with Attention Deficit/Hyperactivity Disorder , 2007, Biological Psychiatry.

[7]  S. Ochudło,et al.  Various patterns of gestes antagonistes in cervical dystonia. , 2007, Parkinsonism & related disorders.

[8]  H. Shill,et al.  Defining mild cognitive impairment in Parkinson's disease , 2007, Movement disorders : official journal of the Movement Disorder Society.

[9]  T. Robbins,et al.  Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. , 2007, Brain : a journal of neurology.

[10]  M. Hallett,et al.  Abnormality of motor cortex excitability in peripherally induced dystonia , 2007, Movement disorders : official journal of the Movement Disorder Society.

[11]  B. Bloem,et al.  Evidence‐based analysis of physical therapy in Parkinson's disease with recommendations for practice and research , 2007, Movement disorders : official journal of the Movement Disorder Society.

[12]  B. Bloem,et al.  Effectiveness of physiotherapy in Parkinson's disease: the feasibility of a randomised controlled trial. , 2007, Parkinsonism & related disorders.

[13]  C. Bjarkam,et al.  Chronic subthalamic high‐frequency deep brain stimulation in Parkinson's disease – a histopathological study , 2007, European journal of neurology.

[14]  G. Kwakkel,et al.  Cueing training in the home improves gait-related mobility in Parkinson’s disease: the RESCUE trial , 2007, Journal of Neurology, Neurosurgery & Psychiatry.

[15]  Claire Ballinger,et al.  A randomised controlled trial of a home based exercise programme to reduce the risk of falling among people with Parkinson’s disease , 2006, Journal of Neurology, Neurosurgery & Psychiatry.

[16]  L. Defebvre,et al.  Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson’s disease , 2006, Journal of Neurology, Neurosurgery & Psychiatry.

[17]  Dieter Vaitl,et al.  Training of executive functions in Parkinson's disease , 2006, Journal of the Neurological Sciences.

[18]  E. Rochtchina,et al.  Prevalence of mitochondrial DNA haplogroups in an Australian population , 2006, Internal medicine journal.

[19]  A. Berardelli,et al.  Botulinum toxin changes intrafusal feedback in dystonia: A study with the tonic vibration reflex , 2006, Movement disorders : official journal of the Movement Disorder Society.

[20]  G. Deuschl,et al.  Deep brain stimulation: Postoperative issues , 2006, Movement disorders : official journal of the Movement Disorder Society.

[21]  T. Robbins,et al.  Neurochemical Modulation of Response Inhibition and Probabilistic Learning in Humans , 2006, Science.

[22]  K. Perry,et al.  Procholinergic and memory enhancing properties of the selective norepinephrine uptake inhibitor atomoxetine , 2006, Molecular Psychiatry.

[23]  F. Pierelli,et al.  Myoclonus of the scapula after acute long thoracic nerve lesion: A case report , 2006, Movement disorders : official journal of the Movement Disorder Society.

[24]  S. Faraone,et al.  Atomoxetine and stroop task performance in adult attention-deficit/hyperactivity disorder. , 2005, Journal of child and adolescent psychopharmacology.

[25]  V. Álvarez,et al.  Mitochondrial DNA polymorphisms and risk of Parkinson's disease in Spanish population , 2005, Journal of the Neurological Sciences.

[26]  Rajesh Pahwa,et al.  Preoperative Clinical Predictors of Response to Bilateral Subthalamic Stimulation in Patients with Parkinson’s Disease , 2005, Stereotactic and Functional Neurosurgery.

[27]  N. Van Blercom,et al.  Efficacy and Safety of Donepezil in the Treatment of Executive Dysfunction in Parkinson Disease: A Pilot Study , 2005, Clinical neuropharmacology.

[28]  M. T. Pellecchia,et al.  Mitochondrial DNA haplogroup K is associated with a lower risk of Parkinson's disease in Italians , 2005, European Journal of Human Genetics.

[29]  S. Lewis,et al.  Mitochondrial DNA haplogroup cluster UKJT reduces the risk of PD , 2005, Annals of neurology.

[30]  M. Schieppati,et al.  Neck proprioception and spatial orientation in cervical dystonia. , 2004, Brain : a journal of neurology.

[31]  J. Caviness,et al.  Myoclonus: current concepts and recent advances , 2004, The Lancet Neurology.

[32]  J. Krauss,et al.  Movement disorders after intervertebral disc surgery: Coincidence or causal relationship? , 2004, Movement disorders : official journal of the Movement Disorder Society.

[33]  M. Trimble,et al.  The syndrome of fixed dystonia: an evaluation of 103 patients. , 2004, Brain : a journal of neurology.

[34]  P. Kelly,et al.  Location of the active contact within the subthalamic nucleus (STN) in the treatment of idiopathic Parkinson's disease. , 2004, Surgical neurology.

[35]  Matthew B. Stern,et al.  Bilateral Stimulation of the Subthalamic Nucleus in Parkinson’s Disease: Surgical Efficacy and Prediction of Outcome , 2004, Stereotactic and Functional Neurosurgery.

[36]  J. Bogousslavsky,et al.  Segmental dystonia induced by wearing glasses with a ribbon: An unusual case of a reverse sensory geste , 2004, Movement disorders : official journal of the Movement Disorder Society.

[37]  W. Otten,et al.  A system of networks and continuing education for physical therapists in rheumatology: a feasibility study , 2004, International journal of integrated care.

[38]  Bastiaan R. Bloem,et al.  Physiotherapy in Parkinson’s disease: utilisation and patient satisfaction , 2004, Journal of Neurology.

[39]  H. Soininen,et al.  Mitochondrial DNA polymorphisms as risk factors for Parkinson’s disease and Parkinson’s disease dementia , 2004, Human Genetics.

[40]  M. Naumann,et al.  Complex mechanisms of sensory tricks in cervical dystonia , 2004, Movement disorders : official journal of the Movement Disorder Society.

[41]  E. Bézard,et al.  High‐frequency stimulation of both zona incerta and subthalamic nucleus induces a normalization of basal ganglia metabolic activity in experimental parkinsonism , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[42]  A. Berardelli,et al.  Central effects of botulinum toxin type A: Evidence and supposition , 2004, Movement disorders : official journal of the Movement Disorder Society.

[43]  K. Aoki,et al.  Subcutaneous administration of botulinum toxin A reduces formalin-induced pain , 2004, Pain.

[44]  Y. Agid,et al.  Parkinson's disease, subthalamic stimulation, and selection of candidates: A pathological study , 2003, Movement disorders : official journal of the Movement Disorder Society.

[45]  G. Kennedy.  STAGED, STAR*D, and PROSPECT Compared: Guidelines for the Pharmacologic Treatment of Late-Life Depression in Primary Care , 2003 .

[46]  C. Clarke,et al.  A Delphi Survey of Best Practice Occupational Therapy for Parkinson's Disease in the United Kingdom , 2003 .

[47]  K. Macey.  Conners' Adult ADHD Rating Scales (CAARS). , 2003 .

[48]  Hon-Man Liu,et al.  Treatment of advanced Parkinson's disease by subthalamotomy: One‐year results , 2003, Movement disorders : official journal of the Movement Disorder Society.

[49]  Y. Agid,et al.  Subthalamic stimulation in Parkinson disease: intraoperative predictive factors. , 2003, Archives of neurology.

[50]  P. Stanzione,et al.  Pramipexole in comparison to l-dopa: a neuropsychological study , 2003, Journal of Neural Transmission.

[51]  D. Middleton,et al.  mt4216C variant in linkage with the mtDNA TJ cluster may confer a susceptibility to mitochondrial dysfunction resulting in an increased risk of Parkinson's disease in the Irish , 2003, Experimental Gerontology.

[52]  J. Haines,et al.  Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. , 2003, American journal of human genetics.

[53]  S. West,et al.  Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies , 2003, Biological Psychiatry.

[54]  A. Tröster,et al.  Prodromal frontal/executive dysfunction predicts incident dementia in Parkinson’s disease , 2003, Journal of the International Neuropsychological Society.

[55]  Y. Ben-Shlomo,et al.  Systematic review of paramedical therapies for Parkinson's disease , 2002, Movement disorders : official journal of the Movement Disorder Society.

[56]  Marjan Jahanshahi,et al.  Clinical features of the geste antagoniste in cervical dystonia. , 2002, Advances in neurology.

[57]  Herta Flor,et al.  Phantom-limb pain: characteristics, causes, and treatment , 2002, The Lancet Neurology.

[58]  Jens Volkmann,et al.  Bilateral high-frequency stimulation in the subthalamic nucleus for the treatment of Parkinson disease: correlation of therapeutic effect with anatomical electrode position. , 2002, Journal of neurosurgery.

[59]  J. Nutt,et al.  Methylphenidate Increases the Motor Effects of L-Dopa in Parkinson's Disease: A Pilot Study , 2001, Clinical neuropharmacology.

[60]  W. Poewe,et al.  Clinical characteristics of the geste antagoniste in cervical dystonia , 2001, Journal of Neurology.

[61]  Y. Ben-Shlomo,et al.  Non-pharmacological therapies for dysphagia in Parkinson's disease. , 2001, The Cochrane database of systematic reviews.

[62]  W. Weiner.  Can peripheral trauma induce dystonia? No! , 2001, Movement disorders : official journal of the Movement Disorder Society.

[63]  J. Jankovic.  Can peripheral trauma induce dystonia and other movement disorders? Yes! , 2001, Movement disorders : official journal of the Movement Disorder Society.

[64]  J. Obeso,et al.  Dorsal subthalamotomy for Parkinson's disease , 2001, Movement disorders : official journal of the Movement Disorder Society.

[65]  J. Ahlskog,et al.  Focal shoulder‐elevation dystonia , 2000, Movement disorders : official journal of the Movement Disorder Society.

[66]  M. Hallett,et al.  Electrophysiological studies of myoclonus , 2000, Muscle & nerve.

[67]  Karlheinz Reiners,et al.  Sensory tricks in cervical dystonia: Perceptual dysbalance of parietal cortex modulates frontal motor programming , 2000, Annals of neurology.

[68]  S. Fahn,et al.  Focal task‐specific dystonia induced by peripheral trauma , 2000, Movement disorders : official journal of the Movement Disorder Society.

[69]  M. Jahanshahi.  Factors that ameliorate or aggravate spasmodic torticollis , 2000, Journal of neurology, neurosurgery, and psychiatry.

[70]  W. Poewe,et al.  Trick maneuvers in cervical dystonia: Investigation of movement‐ and touch‐related changes in polymyographic activity , 1999, Movement disorders : official journal of the Movement Disorder Society.

[71]  S. Faraone,et al.  Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. , 1998, The American journal of psychiatry.

[72]  M. Magistris,et al.  Post-traumatic stimulus suppressible myoclonus of peripheral origin , 1998, Journal of neurology, neurosurgery, and psychiatry.

[73]  S. Bressman,et al.  Exteroceptive and interoceptive stimuli in dystonia , 1998, Movement disorders : official journal of the Movement Disorder Society.

[74]  H. Soininen,et al.  Reduction of noradrenaline impairs attention and dopamine depletion slows responses in Parkinson's disease , 1998, The European journal of neuroscience.

[75]  R. Burke,et al.  Current concepts on the clinical features, aetiology and management of idiopathic cervical dystonia. , 1998, Brain : a journal of neurology.

[76]  Y. Agid,et al.  Attentional deficits in Parkinson's disease: partial reversibility with naphtoxazine (SDZ NVI-085), a selective noradrenergic alpha 1 agonist. , 1998, Clinical neuropharmacology.

[77]  D. Kömpf,et al.  Peripheral myoclonus due to spinal root lesion , 1997, Muscle & nerve.

[78]  Bernard Pillon,et al.  Cognitive deficits in Parkinson’s disease , 1996, Journal of Neurology.

[79]  F. Glocker,et al.  Bilateral myoclonus of the trapezius muscles after distal lesion of an accessory nerve , 1996, Movement disorders : official journal of the Movement Disorder Society.

[80]  J. Speelman,et al.  Quality of life in patients with Parkinson's disease: development of a questionnaire. , 1996, Journal of neurology, neurosurgery, and psychiatry.

[81]  P. Mitchell,et al.  Visual acuity and the causes of visual loss in Australia. The Blue Mountains Eye Study. , 1996, Ophthalmology.

[82]  C. Clarke,et al.  QUALITY OF LIFE AND CARE IN PARKINSON'S DISEASE , 1995, The British journal of clinical practice.

[83]  M. Mega,et al.  The Neuropsychiatric Inventory , 1994, Neurology.

[84]  C. Marsden,et al.  The behavioural and motor consequences of focal lesions of the basal ganglia in man. , 1994, Brain : a journal of neurology.

[85]  J. Hughes,et al.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[86]  G. Deuschl,et al.  Tremor in reflex sympathetic dystrophy. , 1991, Archives of neurology.

[87]  J. Jankovic,et al.  Dystonia and tremor induced by peripheral trauma: predisposing factors. , 1988, Journal of neurology, neurosurgery, and psychiatry.

[88]  C. Grassi,et al.  Action of the sympathetic system on skeletal muscle , 1988, The Italian Journal of Neurological Sciences.

[89]  U. Ahlfors,et al.  The UKU side effect rating scale: A new comprehensive rating scale for psychotropic drugs and a cross‐sectional study of side effects in neuroleptic‐treated patients , 1987, Acta psychiatrica Scandinavica. Supplementum.

[90]  A W Downie,et al.  Parkinson's disease: disability, review, and management. , 1986, British medical journal.

[91]  A. Eisen,et al.  DOUBLE-BLIND STUDY OF BOTULINUM TOXIN IN SPASMODIC TORTICOLLIS , 1986, The Lancet.

[92]  G. Chouinard,et al.  A case of mania associated with tomoxetine. , 1985, The American journal of psychiatry.

[93]  M. Short,et al.  Brachial plexus myoclonus. , 1985, Journal of Neurology Neurosurgery & Psychiatry.

[94]  R. Mayeux,et al.  Reaction time and vigilance in Parkinson's disease. Possible role of altered norepinephrine metabolism. , 1984, Archives of neurology.

[95]  C. Marsden,et al.  Muscle spasms associated with Sudeck's atrophy after injury. , 1984, British medical journal.

[96]  N. Bathien,et al.  [Rhythmic quadriceps myoclonia related to sarcomatous involvement of the crural nerve]. , 1977, Revue neurologique.

[97]  J. Henry,et al.  Effects of substance P on functionally identified units in cat spinal cord , 1976, Brain Research.

[98]  S. Folstein,et al.  “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician , 1975 .

[99]  M. Hoehn,et al.  Parkinsonism , 1967, Neurology.

[100]  Bourdillon Jf.  PHENOTHIAZINE DYSKINESIA AFTER LEUCOTOMY. , 1964, Lancet.

[101]  M. Hamilton.  A RATING SCALE FOR DEPRESSION , 1960, Journal of neurology, neurosurgery, and psychiatry.

[102]  B. Bloem,et al.  Allied health care interventions and complementary therapies in Parkinson's disease. , 2007, Parkinsonism & related disorders.

[103]  N. van Alfen,et al.  The clinical spectrum of neuralgic amyotrophy in 246 cases. , 2006, Brain : a journal of neurology.

[104]  M. Hallett,et al.  Pathophysiology of dystonia. , 2006, Journal of neural transmission. Supplementum.

[105]  G Polo,et al.  Subthalamic nucleus stimulation in Parkinson's disease : anatomical and electrophysiological localization of active contacts. , 2006, Journal of neurology.

[106]  J. Wernicke,et al.  Cardiovascular Effects of Atomoxetine in Children, Adolescents, and Adults , 2003, Drug safety.

[107]  C. Tomlinson,et al.  A comparison of speech and language therapy techniques for dysarthria in Parkinson's disease. , 2001 .

[108]  A. Bonnet,et al.  [The Unified Parkinson's Disease Rating Scale]. , 2000, Revue neurologique.

[109]  S. Gilman,et al.  Diagnostic criteria for Parkinson disease. , 1999, Archives of neurology.

[110]  J. Morris,et al.  Validity and Reliability of the Alzheimer’s Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) , 1997 .

[111]  S H Ferris,et al.  Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. , 1997, Alzheimer disease and associated disorders.

[112]  W. Brouwer,et al.  Training of compensational strategies for impaired gross motor skills in Parkinson's disease , 1995 .

[113]  S. Salloway,et al.  Treatment strategies for patients with dysexecutive syndromes. , 1994, The Journal of neuropsychiatry and clinical neurosciences.

[114]  P. Thompson,et al.  Unusual focal dyskinesias: The ears, the shoulders, the back, and the abdomen , 1994, Movement disorders : official journal of the Movement Disorder Society.

[115]  D. Brooks,et al.  Core assessment program for intracerebral transplantations (CAPIT) , 1992, Movement disorders : official journal of the Movement Disorder Society.

[116]  B. Reisberg.  Functional assessment staging (FAST). , 1988, Psychopharmacology bulletin.

[117]  S. Fahn.  Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale , 1987 .

[118]  M. Hallett,et al.  The nosology and pathophysiology of myoclonus , 1981 .

[119]  E. Mancall,et al.  Painful jumping amputation stumps: pathophysiology of a "sore circuit". , 1974, Transactions of the American Neurological Association.

[120]  Mancall El,et al.  Painful jumping amputation stumps: pathophysiology of a "sore circuit". , 1974 .

[121]  B. Djahanguiri,et al.  The prevention of acute gastric ulcer in the rat by alpha-methyldopa. , 1967, Medicina et pharmacologia experimentalis. International journal of experimental medicine.